Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 8/20 | 0.81 |
| ▸ | RXRA | P19793 | 6/20 | 0.61 |
| ▸ | RXRB | P28702 | 6/20 | 0.61 |
| ▸ | RXRG | P48443 | 6/20 | 0.61 |
| ▸ | RARB | P10826 | 3/20 | 0.61 |
| ▸ | RARG | P13631 | 3/20 | 0.61 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567380 | 1.00 | CYP26A1 (0.81) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL17911573 | 0.89 | CYP26A1 (1.00) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL17911577 | 0.86 | CYP26A1 (0.60) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL24259981 | 0.82 | CYP26A1 (0.57) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL30174998 | 0.82 | CYP26A1 (0.63) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL6148042 | 0.81 | CYP26A1 (0.71) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL17911601 | 0.81 | CYP26A1 (0.55) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL29567408 | 0.81 | CYP26A1 (0.55) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL7759680 | 0.80 | RXRA (0.69) | CYP26A1RXRARXRBRXRGRARB | |
| SCHEMBL24259972 | 0.79 | CYP26A1 (0.76) | CYP26A1RXRARXRBRXRGRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | claimed |
| EP-4083029-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | CYP2B6, CYP26A1, CYP2A6 | CYP26A1 2/4885RXRA 15/4885RXRB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.